Trials / Recruiting
RecruitingNCT07261306
Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Lahore General Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study
Detailed description
Comparison between safety and efficacy of oral methotrexate and tofacitinib in chronic plaque psoriasis is to be determined in this study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methotrexate | Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment |
| DRUG | Tofacitinib | Tofacitinib is janus kinase inhibitor and have role in psoriasis |
Timeline
- Start date
- 2025-08-29
- Primary completion
- 2025-12-10
- Completion
- 2025-12-25
- First posted
- 2025-12-03
- Last updated
- 2025-12-03
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT07261306. Inclusion in this directory is not an endorsement.